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In Response:
We thank Bölükbas et al. for their 
interest in our research. The main issue 
raised by Bölükbas et al. is that survival 
results and pattern of failure were not 
reported in our research, although we 
had a median follow-up of 19 months.
There are two main reasons not to 
present outcome data along with safety 
and feasibility results. First, in the pres-
ent article, we investigated the safety of 
delivering very high doses of radiation 
therapy to the intact lung. Twenty-five 
of 28 patients received 60 Gy in 25 
fractions. Our experience of using high 
radiation dose is the first reported in the 
literature, and we wanted to emphasize 
the toxicity results. Also, Rimner et al.1 
reported initial experience with pleural 
intensity-modulated radiation therapy 
in 36 patients with two intact lungs, 
however, the mean total dose was lower 
(48.6 Gy at 1.8 Gy/fraction). We also 
described the dosimetric performance 
of tomotherapy, and we found that a 
new dosimetric parameter, the contra-
lateral lung V5, was strongly correlated 
with the risk of pneumonitis.
Second, in our opinion, a median 
follow-up of 19 months is not enough 
to draw conclusion on survival. Good 
results in terms of survival were 
obtained with extrapleural pneumo-
nectomy plus radiation; therefore, we 
need very solid data (long follow-up) 
on survival with radical pleurectomy/
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tomotherapy after pleurectomy/decor-
tication or biopsy for malignant pleural 
mesothelioma (MPM). Administration 
of radiation to patients with two intact 
lungs is challenging and the authors 
have to be congratulated for their novel 
approach and the results with regard to 
acute and mid-term toxicities. Safety 
and efficacy have been proved in several 
studies for novel radiation techniques 
in terms of pleural intensity-modulated 
radiation therapy and tomotherapy.2 As 
MPM is a rare and rapidly fatal disease, 
knowledge about disease-free survival, 
overall survival, and patterns of failure 
are of great importance for every study 
reporting outcomes after treatment 
for MPM.
Patterns of local failure might be 
the most important test of adequate treat-
ment planning (clinical target volume 
[CTV]) and treatment success.3 The CTV 
going from the lung apex to the vicin-
ity of the L2 vertebral body is very well 
described. The median follow-up was 
19 months ranging from 6 to 29 months 
in this study. Thus, at least short-term 
and mid-term results should be avail-
able about treatment failures in terms 
of relapse within and/or outside CTV. 
Further more, because the interlobar 
pleura were not included in the CTV it 
would be interesting to see whether there 
were any differences of local recurrence 
within the area of the fissures in patients 
undergoing pleurectomy and patients 
only having undergone biopsy for MPM.
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Study of Lung Cancer Staging Committee 
to develop an international database that 
would lead to evidence-based revisions of 
the International Union Against Cancer 
(UICC) and American Joint Commission 
on Cancer (AJCC) staging system for 
MPM. Discussions of the role of EPP 
in the management of MPM or of the 
MARS trial are, frankly, tangential to the 
primary focus of this effort.
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To the Editor:
We read with great interest the 
important investigation by Minatel 
et al.1 reporting their experience with 
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decortication (P/D) plus intensity-
modulated radiation therapy to com-
pare them with those obtained with 
extrapleural pneumonectomy. The 
multimodality treatment we propose 
(radical P/D followed by high doses 
of radiation) has the potential to be a 
practice-changing approach. Robust 
data are needed to introduce an alter-
native treatment option in this clinical 
setting. With a median follow-up of 19 
months we might show survival results 
only at 1 and 2 years. This can gener-
ate enthusiasm for illusory results. We 
are now submitting to the American 
Society for Radiation Oncology annual 
meeting the survival results updated to 
a median follow-up of 27 months; for 
the group of patients who underwent 
radical P/D, our estimates of overall 
survival at 2 and 3 years are 70% and 
49%, respectively.
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